Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Johnson and Johnson
Dow
McKesson
UBS
Merck
Citi
Accenture

Generated: May 21, 2018

DrugPatentWatch Database Preview

PROCAN SR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Procan Sr, and when can generic versions of Procan Sr launch?

Procan Sr is a drug marketed by Parke Davis and Parkedale and is included in four NDAs.

The generic ingredient in PROCAN SR is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Summary for PROCAN SR
Drug patent expirations by year for PROCAN SR
Medical Subject Heading (MeSH) Categories for PROCAN SR
Synonyms for PROCAN SR
(4-aminophenyl)-N-[2-(diethylamino)ethyl]carboxamide, chloride
4-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
4-Amino-N-(2-(diethylamino)ethyl)benzamide monohydrochloride
4-amino-N-(2-diethylamino-ethyl)-benzamide HCl
4-Amino-N-(2-diethylaminoethyl)benzamide hydrochloride
4-amino-N-[2-(diethylamino)ethyl]-Benzamide hydrochloride
4-amino-N-[2-(diethylamino)ethyl]benzamide hydrochloride
4-amino-N-[2-(diethylamino)ethyl]benzamide;hydrochloride
4-Aminobenzoesaeure-2-diethylaminoethylester hydrochlorid
4-Aminobenzoic acid 2-diethylaminoethylamide
51-06-9 (Parent)
614-39-1
7699-39-0
ABTXGJFUQRCPNH-UHFFFAOYSA-N
AC-7552
AC1L24JW
ACT08464
AK133049
AK500448
AKOS008056264
AN-8900
BC209722
Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-, hydrochloride (1:1)
Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-, monohydrochloride
Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, hydrochloride (1:1)
Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, monohydrochloride
Benzamide, p-amino-N-(2-(diethylamino)ethyl)-, hydrochloride
BIM-0050968.0001
C13H22ClN3O
CAS-614-39-1
CCG-39233
CCRIS 7143
CHEBI:8429
CHEMBL605
CPD000059079
CTK6E8331
D00477
DSSTox_CID_29382
DSSTox_GSID_49422
DSSTox_RID_83497
DTXSID2049422
EBD3071181
EINECS 210-381-7
Epitope ID:140114
EU-0100995
F0850-6742
FT-0603493
HMS1569C15
HMS1920L04
HY-A0084
I01-2626
KB-304279
KS-5258
LP00995
LP052890
LS-25497
M850
MCULE-9726613752
MFCD00012998
MLS000069436
MLS001148635
MolPort-002-319-710
NC00535
NCGC00094291-01
NCGC00094291-02
NCGC00094291-03
NCGC00094291-04
NCGC00094291-05
NCGC00260401-01
NCGC00261680-01
NE10724
Novocamid hydrochloride
NSC-757279
NSC757279
Opera_ID_1543
P 9391
p-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
p-Amino-N-(2-(diethylamino)ethyl)benzamide monohydrochloride
Pharmakon1600-01500503
Procainamide (hydrochloride)
Procainamide Hcl
Procainamide HCL USP
procainamide hydrochloride
Procainamide hydrochloride (JP17/USP)
Procainamide hydrochloride [USAN:JAN]
Procainamide hydrochloride, European Pharmacopoeia (EP) Reference Standard
Procainamide hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur
Procainamide hydrochloride, purum, >=98.0% (AT)
Procainamide hydrochloride, United States Pharmacopeia (USP) Reference Standard
Procainamide, hydrochloride
PROCAINAMIDEHYDROCHLORIDE
Procaine amide hydrochloride
Procainhydrochlorid
Procaini hydrochloridum
Procainii chloridum
Procamide hydrochloride
Procan
Procan SR (TN)
Procan-SR hydrochloride
Procanbid
Procanbid (TN)
Procapan
Procapan hydrochloride
Procardyl hydrochloride
Promide hydrochloride
Pronestyl
Pronestyl (TN)
Pronestyl hydrochloride
PubChem15966
s4294
SAM002554928
SBB001067
SCHEMBL40758
SI4064O0LX
SMR000059079
SPECTRUM1500503
SR-01000000022
SR-01000000022-2
ST50319808
Supicane amide hydrochloride
Tox21_202855
Tox21_500995
TR-034892
UNII-SI4064O0LX
VA11587
VU0239777-5
W-105155

US Patents and Regulatory Information for PROCAN SR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis PROCAN SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 086468-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Parkedale PROCAN SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 087510-001 Apr 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Parkedale PROCAN SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 088489-001 Jan 16, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Parkedale PROCAN SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 086065-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Teva
Medtronic
Cantor Fitzgerald
Queensland Health
Baxter
Farmers Insurance
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.